Olverembatinib for FGFR1-rearranged Neoplasms
Condition(s):Myeloproliferative Neoplasm; Acute LeukemiaLast Updated:August 30, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Myeloproliferative Neoplasm; Acute LeukemiaLast Updated:August 30, 2022Recruiting
Condition(s):Glioblastoma; Adult-type Diffuse GliomasLast Updated:January 19, 2024Active, not recruiting
Condition(s):MPN (Myeloproliferative Neoplasms)Last Updated:December 6, 2023Active, not recruiting
Condition(s):Metastatic Breast CancerLast Updated:December 19, 2020Completed
Condition(s):Gastric Cancer; Oesophageal Cancer; Breast Cancer; Squamous Cell Carcinoma of the LungLast Updated:March 15, 2013Unknown status
Condition(s):Advanced Solid Tumor; CNS Tumor; Recurrent WHO Grade II GliomaLast Updated:February 23, 2023Withdrawn
Condition(s):Solid TumorLast Updated:February 7, 2024Terminated
Condition(s):Bladder CancerLast Updated:December 17, 2019Withdrawn
Condition(s):Gastrointestinal CancerLast Updated:December 15, 2022Recruiting
Condition(s):Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage III Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung CancerLast Updated:June 8, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.